
REGULATORY
23 Apr 2026
Regulators grant priority review to an antibody-drug and immunotherapy regimen intended to reduce recurrence in surgical patients

MARKET TRENDS
2 Apr 2026
US-based manufacturers dominate a sector reshaped by 780 active trials and accelerating reshoring investment

INSIGHTS
30 Mar 2026
A 2026 review urges quantitative proteomics to replace IHC and improve patient selection for ADC cancer therapies

INNOVATION
25 Mar 2026
Starpharma's DEP platform targets ADC toxicity at the delivery level, with a Genentech deal signaling big pharma's interest

INNOVATION
20 Mar 2026
Promatix's AND-gate molecule demonstrated 50-fold potency gains over standard therapy in early colorectal cancer models

INSIGHTS
16 Mar 2026
Experts have revealed five pivotal shifts in drug design, moving toward a future of safer, integrated, and AI-driven cancer therapies
By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.